SEPN Stock — Septerna, Inc. Common Stock

Septerna, Inc. Common Stock (SEPN)

Updated October 16, 2026.

SEPN is a Stock. Total return is 101.9% over the past 2 years, 67.1 points ahead of SPY at 34.8%.

Septerna is a clinical-stage biotechnology company developing oral small molecule drugs that target G protein-coupled receptors (GPCRs) to treat endocrinology, immunology, inflammation, and metabolic diseases, with a collaboration agreement with Novo Nordisk for metabolic-disease therapies. The company does not currently distribute dividends. Septerna appeals to investors with high risk tolerance who seek exposure to early-stage biotech development rather than current income.

SEPN performance versus SPY

Price and return data through 2026-10-16.

Total return is 101.9% over the past 2 years, 67.1 points ahead of SPY at 34.8%. Over the past year its total return — price change plus distributions reinvested — is 61.1%. Its deepest 1-year drawdown was 26.0%.

SEPN key facts

Asset type

Stock

Asset class

Equity

Inception date

10/24/2024

Distribution frequency

None

Last close

$36.35 (as of 2026-10-16)

Market cap

$1,696,707,023

Average volume

234122.0

Payout ratio

0.0%

Forward P/E

107.5269

EPS

$-0.54

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

SEPN risks and drawbacks

The deepest 1-year drawdown on record here is 26.0%.

Who may consider SEPN — and who may not

It is a weaker fit for investors who need monthly cash flow (SEPN does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on SEPN

• All tickers starting with S

Tagged: Healthcare.

Frequently asked questions